COVID-19 Vaccine Comparisons

	PFIZER	MODERNA	JOHNSON & JOHNSON/ JANSSEN
TYPE OF VACCINE	mRNA	mRNA	Adenovirus-based non-replicated viral vector
PROTECTION FROM SEVERE DISEASE	90% clinical trial 97-100% real world	100%	85% (100% after day 49)
PROTECTION FROM HOSPITALIZATION	100% clinical trial 94% real world	100% clinical trial 94% real world	100% clinical trial
PLANS FOR VARIANTS IF EFFICACY DROPS	Booster in development	Booster in development	Booster in development
APPROVED FOR AGES	12 and over	18 and over	18 and over with FDA warning for blood clots
NUMBER OF REQUIRED DOSES	2	2	1
DOSE INTERVALS	3 weeks	4 weeks	N/A
STORAGE INFORMATION	-25 to -15 C	-25 to -15 C	2 to 8 C
PEDIATRIC AUTHORIZATION	Authorized 12 and over, childhood trial in progress	Adolescent trial ongoing, childhood trial started	Enrolling childhood trial
PREGNANCY AUTHORIZATION	*DART complete, no adverse events	*DART complete, no adverse events	*DART complete, no adverse events
BLA STATUS **	Application submitted	Application date tbd	Application date tbd

*Developmental and Reproductive Toxicology (DART)

**Biologics License Applications (BLA) Process

Last updated 5/14/2021.